BACKGROUND: Outcome of streptococcal prosthetic hip infection is often thought to be better than that caused by other pathogens. That supposition was not confirmed in our experience with group B streptococcal prosthetic joint infection. OBJECTIVE: We compared outcomes of group B streptococcal and other-pathogen prosthetic hip infections. METHODS: One hundred and thirty nine patients, 24 with group B streptococcal and 115 other-pathogen prosthetic hip infections, were included. The primary outcome was the time from surgical treatment to treatment failure, defined as relapse, infection- or treatment-related death. Secondary outcomes were the times from surgical treatment to relapse or any event (event-free survival). The cumulative incidence estimator was used to model primary and secondary outcomes. Multivariable regression analysis was used to determine a set of independent predictors of treatment failure. RESULTS: With a median follow-up of 22 months, treatment failed more frequently in patients with group B streptococcal prosthetic hip infections (hazard ratio, 4.88 [95% CI, 1.4-17], P=.012). Multivariable analysis retained the American Society of Anesthesiologist score and group B streptococcal infection as independent risk factors of treatment failure; event-free survival was lower for these patients (hazard ratio, 2.64 [95% CI, 1.2-6], P=.02). CONCLUSION: Despite high antibiotic susceptibility, outcomes of group B streptococcal and other-pathogen prosthetic hip infection differ.
BACKGROUND: Outcome of streptococcal prosthetic hip infection is often thought to be better than that caused by other pathogens. That supposition was not confirmed in our experience with group B streptococcal prosthetic joint infection. OBJECTIVE: We compared outcomes of group B streptococcal and other-pathogen prosthetic hip infections. METHODS: One hundred and thirty nine patients, 24 with group B streptococcal and 115 other-pathogen prosthetic hip infections, were included. The primary outcome was the time from surgical treatment to treatment failure, defined as relapse, infection- or treatment-related death. Secondary outcomes were the times from surgical treatment to relapse or any event (event-free survival). The cumulative incidence estimator was used to model primary and secondary outcomes. Multivariable regression analysis was used to determine a set of independent predictors of treatment failure. RESULTS: With a median follow-up of 22 months, treatment failed more frequently in patients with group B streptococcal prosthetic hip infections (hazard ratio, 4.88 [95% CI, 1.4-17], P=.012). Multivariable analysis retained the American Society of Anesthesiologist score and group B streptococcal infection as independent risk factors of treatment failure; event-free survival was lower for these patients (hazard ratio, 2.64 [95% CI, 1.2-6], P=.02). CONCLUSION: Despite high antibiotic susceptibility, outcomes of group B streptococcal and other-pathogen prosthetic hip infection differ.
Authors: S Corvec; M Illiaquer; S Touchais; D Boutoille; N van der Mee-Marquet; R Quentin; A Reynaud; D Lepelletier; P Bémer Journal: J Clin Microbiol Date: 2010-11-10 Impact factor: 5.948
Authors: Y Maaloum; A Meybeck; D Olive; N Boussekey; P-Y Delannoy; A Chiche; H Georges; E Beltrand; E Senneville; T d'Escrivan; O Leroy Journal: Infection Date: 2012-10-25 Impact factor: 3.553
Authors: Elysia A Masters; Stephanie P Hao; H Mark Kenney; Yugo Morita; Chad A Galloway; Karen L de Mesy Bentley; Benjamin F Ricciardi; Brendan F Boyce; Edward M Schwarz; Irvin Oh Journal: J Orthop Res Date: 2020-12-29 Impact factor: 3.494
Authors: E Fiaux; M Titecat; O Robineau; J Lora-Tamayo; Y El Samad; M Etienne; N Frebourg; N Blondiaux; B Brunschweiler; F Dujardin; E Beltrand; C Loiez; V Cattoir; J P Canarelli; C Hulet; M Valette; S Nguyen; F Caron; H Migaud; E Senneville Journal: BMC Infect Dis Date: 2016-10-13 Impact factor: 3.090
Authors: Paul Loubet; Yatrika Koumar; Catherine Lechiche; Nicolas Cellier; Sophie Schuldiner; Pascal Kouyoumdjian; Jean-Philippe Lavigne; Albert Sotto Journal: PLoS One Date: 2021-03-12 Impact factor: 3.240